Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $6,314 | $10,130 | $13,538 | $18,948 |
| Operating expenses: | ||||
| Research and development(1) | 64,330 | 59,735 | 122,142 | 106,560 |
| General and administrative(2) | 13,598 | 10,545 | 27,122 | 20,692 |
| Total operating expenses | 77,928 | 70,280 | 149,264 | 127,252 |
| Loss from operations | (71,614) | (60,150) | (135,726) | (108,304) |
| Other income (expense), net | ||||
| Change in fair value of convertible preferred stock warrant liability | — | — | (363) | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s G&A?
- Generate Biomedicines, Inc. (GENB) reported G&A of $13.6M in Q2 2026.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Generate Biomedicines, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude